Cravens & Co Advisors’s Pfizer PFE Stock Holding History

Cravens & Co Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-19,135	Closed	-$531K	–	76
2024 Q1	$531K	Buy	19,135 +1,681	+10%	+$46.6K	0.44%	43
2023 Q4	$503K	Sell	17,454 -5,758	-25%	-$174K	0.43%	44
2023 Q3	$770K	Buy	23,212 +1,620	+8%	+$57.3K	0.72%	32
2023 Q2	$792K	Sell	21,592 -49	-0.2%	-$1.91K	0.73%	32
2023 Q1	$883K	Sell	21,641 -87	-0.4%	-$3.76K	0.82%	24
2022 Q4	$1.11M	Buy	+21,728	New	+$1.04M	1.03%	14

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Cravens & Co Advisors's PFE Position: Q2 2024 in Review

Cravens & Co Advisors sold out of Pfizer (PFE) in Q2 2024, closing a stake of 19,135 shares — an estimated $531K sold.

Cravens & Co Advisors first reported a position in PFE in Q4 2022 and held it in 6 quarters. The position peaked at $1.11M in Q4 2022. 2,873 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

Cravens & Co Advisors reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
Cravens & Co Advisors sold 19,135 Pfizer shares in Q2 2024, an estimated $531K.
Cravens & Co Advisors first reported a position in Pfizer in Q4 2022 and held it in 6 quarters.
Cravens & Co Advisors's Pfizer position peaked at $1.11M in Q4 2022.
2,873 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on Cravens & Co Advisors's 13F filing for Q2 2024, filed 1 Aug 2024.